Advanced in Stomach Cancer

Nuria J. Sala

Soria, CL, ES 
Advanced in Stomach Cancer
Soria, CL, ES 
OverviewLocationsClinical Research

Overview

Nuria Sala practices in Soria, Spain. Ms. Sala is rated as an Advanced expert by MediFind in the treatment of Stomach Cancer. Her top areas of expertise are Stomach Cancer, Prostate Cancer, Urothelial Cancer, and Colorectal Cancer.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 21 articles in the study of Stomach Cancer.

Gender
Female

Locations

Soria, CL, Spain
Other Locations
Barcelona, CT 08908, Spain
Girona, CT, Spain
Madrid, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy
A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy
Enrollment Status: Completed
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drugs: Niraparib, Cabozantinib
Study Phase: Phase 1/Phase 2
A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Enrollment Status: Unknown
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Docetaxel, ADT
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

63 Total Publications

CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions.
CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: December 07, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sala's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile